AgomAb Therapeutics NV (NASDAQ:AGMB) Receives Consensus Rating of “Moderate Buy” from Brokerages

AgomAb Therapeutics NV (NASDAQ:AGMB) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $32.00.

AGMB has been the topic of a number of recent research reports. JPMorgan Chase & Co. assumed coverage on shares of AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price objective on the stock. Morgan Stanley assumed coverage on shares of AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price objective on the stock. HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a research note on Monday. They set a “buy” rating on the stock. Leerink Partners assumed coverage on shares of AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 price objective on the stock. Finally, Zacks Research upgraded shares of AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th.

AgomAb Therapeutics Stock Performance

AGMB stock opened at $10.98 on Monday. AgomAb Therapeutics has a 1 year low of $8.75 and a 1 year high of $17.45. The company has a fifty day moving average of $10.96.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.